Travere Therapeutics (TVTX) Stock Price, Quote, News & History | Benzinga

Travere Therapeutics Inc (TVTX) Stock Price, Quote, News & History

TVTXNASDAQ

Trade with Public

Trade with Public

$65.71

-0.57-0.86%

At close: Aug 31, 5:00 PM EST

$65.90

-0.38-0.57%

Pre-Market: 8:39 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$65.71

Volume / Avg.

1.57K / 1.78M

Day Range

- - -

52 Wk Range

17.27 - 67.85

Market Cap

$6.13B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

60

Short Interest

16.79%

Days to Cover

5.7

Recent Travere Therapeutics, Inc. News

Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday

US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies recording gains in today's session.

Avi Kapoor

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.

Mohd Haider

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.

Avi Kapoor

Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views

Dow Jones up 200 points, consumer discretionary shares rise 1.8%, Wells Fargo reports worse-than-expected earnings, Avanos Medical surges 69%.

Avi Kapoor

Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday

Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TVTX, BE, IONQ, SANA, RGTI, VACH, AOSL.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

92.70M

Investing Cash Flow (TTM)

-202.99M

Financing Cash Flow (TTM)

153.06M

Free Cash Flow (TTM)

15.16M

Capital Expenditure (TTM)

-77.54M

Net Change in Cash (TTM)

42.78M

Analyst Trends and Forecast

5

May

8

Jun

1

Jul

7

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.32B

PE Ratio (TTM)

-

PE Ratio (FWD)

43.86

PEG Ratio (TTM)

-

PS Ratio (TTM)

10.14

PB Ratio (TTM)

252.62

Earnings Yield % (TTM)

-1.11%

Earnings Yield % (FWD)

2.28%

EV / EBITDA (TTM)

1094.44

Price / EBITDA (TTM)

1037.79

Price / Free Cash Flow (TTM)

395.36

Book Value / Share

$0.26

Company Debt

Total Debt

$602.78M

LT Debt

$602.78M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$419.79M

Total Cash

$117.74M

Debt to Equity

25.16

Issuance of Debt (TTM)

$105.21M

Repayment of Debt (TTM)

-$419.79M

Key Statistics

Open

-

Close

$65.71

Volume / Avg.

1.57K / 1.78M

Day Range

- - -

52 Wk Range

17.27 - 67.85

Market Cap

$6.13B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

60

Short Interest

16.79%

Days to Cover

5.7

About

Sector

Health Care

Industry

Biotechnology

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Travere Therapeutics (TVTX) stock?

A

You can purchase shares of Travere Therapeutics (NASDAQ:TVTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Travere Therapeutics (TVTX) competitors?

A

Other companies in Travere Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Travere Therapeutics (TVTX) stock?

A

Travere Therapeutics has a consensus price target of $49.39.

Q

What is the current price for Travere Therapeutics (TVTX)?

A

The stock price for Travere Therapeutics (NASDAQ: TVTX) is $65.9 last updated September 2, 2026 at 4:59 AM EDT.

Q

Does Travere Therapeutics (TVTX) pay a dividend?

A

There are no upcoming dividends for Travere Therapeutics.

Q

When is Travere Therapeutics (NASDAQ:TVTX) reporting earnings?

A

Travere Therapeutics does not have any upcoming earnings scheduled.

Q

Is Travere Therapeutics (TVTX) going to split?

A

There is no upcoming split for Travere Therapeutics.

Q

What sector and industry does Travere Therapeutics (TVTX) operate in?

A

Travere Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.